Andrew J Mclachlan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9418948/publications.pdf

Version: 2024-02-01

334 papers 15,091 citations

18436 62 h-index 108 g-index

341 all docs

341 docs citations

times ranked

341

16669 citing authors

#	Article	IF	CITATIONS
1	Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. Journal of Clinical Epidemiology, 2012, 65, 989-995.	2.4	891
2	Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. BMJ, The, 2015, 350, h1225-h1225.	3.0	416
3	Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. Thrombosis and Haemostasis, 2014, 111, 1167-1176.	1.8	407
4	Clinical Pharmacokinetics and Pharmacodynamics of Celecoxib. Clinical Pharmacokinetics, 2000, 38, 225-242.	1.6	358
5	Effectiveness of pharmacist-led medication reconciliation programmes on clinical outcomes at hospital transitions: a systematic review and meta-analysis. BMJ Open, 2016, 6, e010003.	0.8	323
6	Medication Withdrawal Trials in People Aged 65 Years and Older. Drugs and Aging, 2008, 25, 1021-1031.	1.3	274
7	Efficacy, Tolerability, and Dose-Dependent Effects of Opioid Analgesics for Low Back Pain. JAMA Internal Medicine, 2016, 176, 958.	2.6	258
8	Efficacy of paracetamol for acute low-back pain: a double-blind, randomised controlled trial. Lancet, The, 2014, 384, 1586-1596.	6.3	255
9	Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. British Journal of Clinical Pharmacology, 2004, 57, 592-599.	1.1	246
10	High-Risk Prescribing and Incidence of Frailty Among Older Community-Dwelling Men. Clinical Pharmacology and Therapeutics, 2012, 91, 521-528.	2.3	245
11	Clinical pharmacology in the geriatric patient. Fundamental and Clinical Pharmacology, 2007, 21, 217-230.	1.0	242
12	Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring. Antimicrobial Agents and Chemotherapy, 2012, 56, 4793-4799.	1.4	241
13	Pharmacy-led medication reconciliation programmes at hospital transitions: a systematic review and meta-analysis. Journal of Clinical Pharmacy and Therapeutics, 2016, 41, 128-144.	0.7	217
14	Too much medicine in older people? Deprescribing through shared decision making. BMJ, The, 2016, 353, i2893.	3.0	204
15	Assessment of diclofenac or spinal manipulative therapy, or both, in addition to recommended first-line treatment for acute low back pain: a randomised controlled trial. Lancet, The, 2007, 370, 1638-1643.	6.3	203
16	Low Back Pain and Best Practice Care. Archives of Internal Medicine, 2010, 170, 271.	4.3	203
17	Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. British Journal of Clinical Pharmacology, 2005, 59, 425-432.	1.1	200
18	Epidural Corticosteroid Injections in the Management of Sciatica. Annals of Internal Medicine, 2012, 157, 865.	2.0	200

#	Article	IF	CITATIONS
19	Clinical pharmacology of analgesic medicines in older people: impact of frailty and cognitive impairment. British Journal of Clinical Pharmacology, 2011, 71, 351-364.	1.1	175
20	Multicenter Study of Posaconazole Therapeutic Drug Monitoring: Exposure-Response Relationship and Factors Affecting Concentration. Antimicrobial Agents and Chemotherapy, 2012, 56, 5503-5510.	1.4	164
21	Trial of Pregabalin for Acute and Chronic Sciatica. New England Journal of Medicine, 2017, 376, 1111-1120.	13.9	164
22	Drugs for relief of pain in patients with sciatica: systematic review and meta-analysis. BMJ: British Medical Journal, 2012, 344, e497-e497.	2.4	162
23	Clinical Pharmacokinetics and Pharmacodynamics of Allopurinol and Oxypurinol. Clinical Pharmacokinetics, 2007, 46, 623-644.	1.6	153
24	Imatinib Disposition and ABCB1 (MDR1, P-Glycoprotein) Genotype. Clinical Pharmacology and Therapeutics, 2007, 82, 33-40.	2.3	135
25	Posaconazole Exposure-Response Relationship: Evaluating the Utility of Therapeutic Drug Monitoring. Antimicrobial Agents and Chemotherapy, 2012, 56, 2806-2813.	1.4	134
26	Curcumin as a clinically-promising anti-cancer agent: pharmacokinetics and drug interactions. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 953-972.	1.5	125
27	Anticonvulsants in the treatment of low back pain and lumbar radicular pain: a systematic review and meta-analysis. Cmaj, 2018, 190, E786-E793.	0.9	125
28	The experiences of implementing generic medicine policy in eight countries: A review and recommendations for a successful promotion of generic medicine use. Saudi Pharmaceutical Journal, 2014, 22, 491-503.	1.2	116
29	Drug Metabolism in Older People-A Key Consideration in Achieving Optimal Outcomes With Medicines. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2012, 67A, 175-180.	1.7	115
30	A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia. Leukemia and Lymphoma, 2015, 56, 1406-1415.	0.6	111
31	Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. British Journal of Pharmacology, 2008, 154, 1691-1700.	2.7	109
32	Ethnic differences in drug metabolism and toxicity from chemotherapy. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 243-257.	1.5	106
33	Enhancing pharmacists' role in developing countries to overcome the challenge of antimicrobial resistance: a narrative review. Antimicrobial Resistance and Infection Control, 2018, 7, 63.	1.5	99
34	Population Pharmacokinetics of Liposomal Amphotericin B in Pediatric Patients with Malignant Diseases. Antimicrobial Agents and Chemotherapy, 2006, 50, 935-942.	1.4	98
35	Factors affecting variability in distribution of tacrolimus in liver transplant recipients. British Journal of Clinical Pharmacology, 2003, 57, 298-309.	1.1	95
36	Impact of Residential Medication Management Reviews on Drug Burden Index in Aged-Care Homes. Drugs and Aging, 2009, 26, 677-686.	1.3	95

#	Article	IF	CITATIONS
37	Decision-Making Preferences and Deprescribing: Perspectives of Older Adults and Companions About Their Medicines. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2018, 73, e98-e107.	2.4	94
38	Non-prescription sales of antimicrobial agents at community pharmacies in developing countries: a systematic review. International Journal of Antimicrobial Agents, 2018, 52, 771-782.	1.1	94
39	Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with racâ€warfarin [see comments]. British Journal of Clinical Pharmacology, 1994, 37, 563-569.	1.1	93
40	Community pharmacy services to optimise the use of medications for mental illness: a systematic review. Australia and New Zealand Health Policy, 2005, 2, 29.	2.2	91
41	Variability in Response to Medicines in Older People: Phenotypic and Genotypic Factors. Clinical Pharmacology and Therapeutics, 2009, 85, 431-433.	2.3	91
42	Investigating polypharmacy and drug burden index in hospitalised older people. Internal Medicine Journal, 2013, 43, 912-918.	0.5	91
43	Stereochemical aspects of warfarin drug interactions: Use of a combined pharmacokinetic-pharmacodynamic model. Clinical Pharmacology and Therapeutics, 1994, 56, 286-294.	2.3	90
44	Psychotropic Prescribing in Long-Term Care Facilities: Impact of Medication Reviews and Educational Interventions. American Journal of Geriatric Psychiatry, 2008, 16, 621-632.	0.6	87
45	Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: Effect of induction by rifampin and ethnicity. Clinical Pharmacology and Therapeutics, 2006, 80, 75-84.	2.3	86
46	Effects of St John's wort and <i>CYP2C9</i> genotype on the pharmacokinetics and pharmacodynamics of gliclazide. British Journal of Pharmacology, 2008, 153, 1579-1586.	2.7	82
47	Paracetamol versus placebo for knee and hip osteoarthritis. The Cochrane Library, 2019, 2019, CD013273.	1.5	82
48	Efficacy and tolerability of muscle relaxants for low back pain: Systematic review and metaâ€analysis. European Journal of Pain, 2017, 21, 228-237.	1.4	81
49	Validation of methods to study the distribution and protein binding of tacrolimus in human blood. Journal of Pharmacological and Toxicological Methods, 2001, 46, 27-35.	0.3	80
50	Investigation of the Effects of Herbal Medicines on Warfarin Response in Healthy Subjects: A Population Pharmacokinetic-Pharmacodynamic Modeling Approach. Journal of Clinical Pharmacology, 2006, 46, 1370-1378.	1.0	78
51	Voriconazole pharmacokinetics and exposure–response relationships: Assessing the links between exposure, efficacy and toxicity. International Journal of Antimicrobial Agents, 2014, 44, 183-193.	1.1	77
52	Efficacy and safety of antidepressants for the treatment of back pain and osteoarthritis: systematic review and meta-analysis. BMJ, The, 2021, 372, m4825.	3.0	77
53	Principles and Clinical Application of Assessing Alterations in Renal Elimination Pathways. Clinical Pharmacokinetics, 2003, 42, 1193-1211.	1.6	76
54	Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing. Journal of Antimicrobial Chemotherapy, 2014, 69, 1633-1641.	1.3	76

#	Article	IF	Citations
55	Evidence-based toxicity evaluation and scheduling of Chinese herbal medicines. Journal of Ethnopharmacology, 2013, 146, 40-61.	2.0	74
56	Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy. Annual Review of Pharmacology and Toxicology, 2021, 61, 225-245.	4.2	74
57	Impact of electronic medication reconciliation interventions on medication discrepancies at hospital transitions: a systematic review and meta-analysis. BMC Medical Informatics and Decision Making, 2016, 16, 112.	1.5	73
58	Pharmacokinetics of Nonsteroidal Anti-Inflammatory Drugs in Synovial Fluid. Clinical Pharmacokinetics, 1999, 36, 191-210.	1.6	67
59	Physiologically Based Pharmacokinetic Model for Terbinafine in Rats and Humans. Antimicrobial Agents and Chemotherapy, 2002, 46, 2219-2228.	1.4	67
60	HPLC assay for bupropion and its major metabolites in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 823, 115-121.	1.2	66
61	Population pharmacokinetics and dosing regimen design of milrinone in preterm infants. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2007, 92, F204-F209.	1.4	66
62	Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. British Journal of Clinical Pharmacology, 2010, 69, 484-497.	1.1	66
63	Measurement of CYP1A2 Activity: A Focus on Caffeine as a Probe. Current Drug Metabolism, 2012, 13, 667-678.	0.7	66
64	Understanding Variability in Posaconazole Exposure Using an Integrated Population Pharmacokinetic Analysis. Antimicrobial Agents and Chemotherapy, 2014, 58, 6879-6885.	1.4	65
65	Pilot study of milrinone for low systemic blood flow in very preterm infants. Journal of Pediatrics, 2006, 148, 306-313.	0.9	64
66	A retrospective study of drugâ€related problems in Australian aged care homes: medication reviews involving pharmacists and general practitioners. Journal of Evaluation in Clinical Practice, 2011, 17, 97-103.	0.9	64
67	Fruit Juices as Perpetrators of Drug Interactions: The Role of Organic Anion–Transporting Polypeptides. Clinical Pharmacology and Therapeutics, 2012, 92, 622-630.	2.3	64
68	Understanding drug interactions with St John's wort (<i>Hypericum perforatum</i> L.): impact of hyperforin content. Journal of Pharmacy and Pharmacology, 2018, 71, 129-138.	1.2	64
69	Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. British Journal of Clinical Pharmacology, 2003, 57, 44-53.	1.1	63
70	Atrial fibrillation screening in pharmacies using an iPhone ECG: a qualitative review of implementation. International Journal of Clinical Pharmacy, 2015, 37, 1111-1120.	1.0	63
71	Prevalence of Potentially Inappropriate Medication Use in Older Inpatients with and without Cognitive Impairment: A Systematic Review. Journal of Alzheimer's Disease, 2018, 61, 1639-1652.	1.2	63
72	Adverse Drug Events and Medication Errors in African Hospitals: A Systematic Review. Drugs - Real World Outcomes, 2018, 5, 1-24.	0.7	61

#	Article	IF	CITATIONS
73	Amphotericin B in Children with Malignant Disease: a Comparison of the Toxicities and Pharmacokinetics of Amphotericin B Administered in Dextrose versus Lipid Emulsion. Antimicrobial Agents and Chemotherapy, 1999, 43, 1417-1423.	1.4	60
74	Vancomycin pharmacokinetics in patients with severe burn injuries. Burns, 2010, 36, 469-476.	1.1	60
75	Predictors of Vinorelbine Pharmacokinetics and Pharmacodynamics in Patients With Cancer. Journal of Clinical Oncology, 2006, 24, 2448-2455.	0.8	58
76	Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics. Journal of Pharmacy and Pharmacology, 2011, 63, 1161-1168.	1.2	58
77	Drug-Related Problems in the Community Setting. Clinical Drug Investigation, 2006, 26, 415-425.	1.1	57
78	Pharmacokinetic and Pharmacodynamic Interaction Between Allopurinol and Probenecid in Patients with Gout. Journal of Rheumatology, 2011, 38, 904-910.	1.0	56
79	The efficacy of conservative treatment of osteoporotic compression fractures on acute pain relief: a systematic review with meta-analysis. European Spine Journal, 2015, 24, 702-714.	1.0	56
80	Changes in Tacrolimus Distribution in Blood and Plasma Protein Binding Following Liver Transplantation. Therapeutic Drug Monitoring, 2004, 26, 506-515.	1.0	54
81	The deprescribing rainbow: a conceptual framework highlighting the importance of patient context when stopping medication in older people. BMC Geriatrics, 2018, 18, 295.	1.1	54
82	Pharmacokinetics of fluconazole in people with HIV infection: a population analysis. British Journal of Clinical Pharmacology, 1996, 41, 291-298.	1.1	52
83	Pharmacokinetics of Ciprofloxacin in the Human Eye: a Clinical Study and Population Pharmacokinetic Analysis. Antimicrobial Agents and Chemotherapy, 2000, 44, 1674-1679.	1.4	52
84	Population Pharmacokinetic Estimation of Tacrolimus Apparent Clearance in Adult Liver Transplant Recipients. Therapeutic Drug Monitoring, 2005, 27, 422-430.	1.0	51
85	Psychotropic medication use in Australia, 2007 to 2015: Changes in annual incidence, prevalence and treatment exposure. Australian and New Zealand Journal of Psychiatry, 2017, 51, 990-999.	1.3	51
86	Plasma protein binding of the enantiomers of hydroxychloroquine and metabolites. European Journal of Clinical Pharmacology, 1993, 44, 481-484.	0.8	50
87	Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic. British Journal of Clinical Pharmacology, 2005, 60, 291-299.	1.1	50
88	Aging Biology and Novel Targets for Drug Discovery. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2012, 67A, 168-174.	1.7	48
89	Herbal medicines: challenges in the modern world. Part 1. Australia and New Zealand. Expert Review of Clinical Pharmacology, 2016, 9, 905-915.	1.3	48
90	Efficacy and Safety of Oral and Transdermal Opioid Analgesics for Musculoskeletal Pain in Older Adults: A Systematic Review of Randomized, Placebo-Controlled Trials. Journal of Pain, 2018, 19, 475.e1-475.e24.	0.7	48

#	Article	IF	Citations
91	The impact of frailty on pharmacokinetics in older people: using gentamicin population pharmacokinetic modeling to investigate changes in renal drug clearance by glomerular filtration. European Journal of Clinical Pharmacology, 2014, 70, 549-555.	0.8	46
92	Measuring anticholinergic drug exposure in older communityâ€dwelling Australian men: a comparison of four different measures. British Journal of Clinical Pharmacology, 2015, 80, 1169-1175.	1.1	46
93	Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients. British Journal of Clinical Pharmacology, 1997, 44, 537-542.	1.1	45
94	Influence of Environmental and Genetic Factors on CYP1A2 Activity in Individuals of South Asian and European Ancestry. Clinical Pharmacology and Therapeutics, 2012, 92, 511-9.	2.3	45
95	Interventions Available Over the Counter and Advice for Acute Low Back Pain: Systematic Review and Meta-Analysis. Journal of Pain, 2014, 15, 2-15.	0.7	45
96	Influence of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Sulfonylurea Drugs. Current Drug Metabolism, 2009, 10, 643-658.	0.7	44
97	Statin use and clinical outcomes in older men: a prospective population-based study. BMJ Open, 2013, 3, e002333.	0.8	44
98	The efficacy and safety of paracetamol for pain relief: an overview of systematic reviews. Medical Journal of Australia, 2021, 214, 324-331.	0.8	44
99	High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation. British Journal of Clinical Pharmacology, 2016, 82, 149-159.	1.1	43
100	Clinical Outcomes of a Collaborative, Home-Based Postdischarge Warfarin Management Service. Annals of Pharmacotherapy, 2011, 45, 325-334.	0.9	42
101	Adverse Selection? A Multi-Dimensional Profile of People Dispensed Opioid Analgesics for Persistent Non-Cancer Pain. PLoS ONE, 2013, 8, e80095.	1.1	42
102	Investigating knowledge regarding antibiotics and antimicrobial resistance among pharmacy students in Sri Lankan universities. BMC Infectious Diseases, 2018, 18, 209.	1.3	42
103	What proportion of patients with chronic noncancer pain are prescribed an opioid medicine? Systematic review and metaâ€regression of observational studies. Journal of Internal Medicine, 2020, 287, 458-474.	2.7	42
104	Population Pharmacokinetics and Pharmacodynamics: An Underutilized Resource. Drug Information Journal, 1998, 32, 693-710.	0.5	40
105	Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma. Biomedical Chromatography, 2010, 24, 1136-1144.	0.8	40
106	Population pharmacokinetics of amphotericin B in children with malignant diseases. British Journal of Clinical Pharmacology, 2001, 52, 671-680.	1.1	39
107	Anticholinergic Activity of Commonly Prescribed Medications and Neuropsychiatric Adverse Events in Older People. Journal of Clinical Pharmacology, 2009, 49, 1176-1184.	1.0	38
108	High-performance liquid chromatographic separation of the enantiomers of hydroxychloroquine and its major metabolites in biological fluids using an $\hat{l}\pm 1$ -acid glycoprotein stationary phase. Biomedical Applications, 1991, 570, 119-127.	1.7	37

#	Article	IF	Citations
109	The pharmacogenomics of statins. Pharmacological Research, 2014, 88, 99-106.	3.1	37
110	Disposition of the enantiomers of hydroxychloroquine in patients with rheumatoid arthritis following multiple doses of the racemate British Journal of Clinical Pharmacology, 1993, 36, 78-81.	1.1	36
111	BIOAVAILABILITY OF HYDROXYCHLOROQUINE TABLETS IN PATIENTS WITH RHEUMATOID ARTHRITIS. Rheumatology, 1994, 33, 235-239.	0.9	36
112	Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. Thrombosis and Haemostasis, 2007, 97, 922-930.	1.8	36
113	Age-Related Pseudocapillarization of the Liver Sinusoidal Endothelium Impairs the Hepatic Clearance of Acetaminophen in Rats. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2011, 66A, 400-408.	1.7	36
114	In Vitro Characterization of the Human Liver Microsomal Kinetics and Reaction Phenotyping of Olanzapine Metabolism. Drug Metabolism and Disposition, 2015, 43, 1806-1814.	1.7	36
115	Lifeâ€threatening drug interactions: what the physician needs to know. Internal Medicine Journal, 2017, 47, 501-512.	0.5	36
116	Pharmacokinetic and pharmacodynamic interactions of echinacea and policosanol with warfarin in healthy subjects. British Journal of Clinical Pharmacology, 2010, 69, 508-515.	1.1	35
117	A High-Throughput Assay Using Liquid Chromatography-Tandem Mass Spectrometry for Simultaneous In Vivo Phenotyping of 5 Major Cytochrome P450 Enzymes in Patients. Therapeutic Drug Monitoring, 2009, 31, 239-246.	1.0	34
118	Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1115-1137.	1.5	34
119	Terbinafine in Combination with Other Antifungal Agents for Treatment of Resistant or Refractory Mycoses: Investigating Optimal Dosing Regimens Using a Physiologically Based Pharmacokinetic Model. Antimicrobial Agents and Chemotherapy, 2014, 58, 48-54.	1.4	34
120	Pharmacokinetic and Pharmacodynamic Interaction between Allopurinol and Probenecid??in Healthy Subjects. Clinical Pharmacokinetics, 2008, 47, 111-118.	1.6	33
121	Prescribing for Australians living with dementia: study protocol using the Delphi technique. BMJ Open, 2015, 5, e008048.	0.8	33
122	Combination Drug Therapy for the Management of Low Back Pain and Sciatica: Systematic Review and Meta-Analysis. Journal of Pain, 2019, 20, 1-15.	0.7	33
123	Determinants of antipsychotic medication use among older people living in aged care homes in Australia. International Journal of Geriatric Psychiatry, 2010, 25, 449-457.	1.3	32
124	High risk prescribing in older adults: prevalence, clinical and economic implications and potential for intervention at the population level. BMC Public Health, 2013, 13, 115.	1.2	32
125	PACE - The first placebo controlled trial of paracetamol for acute low back pain: design of a randomised controlled trial. BMC Musculoskeletal Disorders, 2010, 11, 169.	0.8	31
126	Epidural corticosteroid injections for lumbosacral radicular pain. The Cochrane Library, 2020, 2020, CD013577.	1.5	31

#	Article	IF	Citations
127	Effect of Metabolic Inhibitors on Cyclosporine Pharmacokinetics Using a Population Approach. Therapeutic Drug Monitoring, 1998, 20, 390-395.	1.0	31
128	Worsening trends in analgesics recommended for spinal pain in primary care. European Spine Journal, 2018, 27, 1136-1145.	1.0	30
129	Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in Paediatrics. Frontiers in Pharmacology, 2020, 10, 1672.	1.6	30
130	Pharmacokinetics and pharmacodynamics of hydroxychloroquine enantiomers in patients with rheumatoid arthritis receiving multiple doses of racemate. Chirality, 1994, 6, 355-359.	1.3	28
131	Distribution kinetics of salicylic acid in the isolated perfused rat liver assessed using moment analysis and the two-compartment axial dispersion model. Pharmaceutical Research, 1994, 11, 1337-1345.	1.7	28
132	Determination of terbinafine in tissues. Biomedical Chromatography, 2000, 14, 261-268.	0.8	28
133	Stereoselective analysis of hydroxybupropion and application to drug interaction studies. Chirality, 2007, 19, 163-170.	1.3	28
134	Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study. British Journal of Clinical Pharmacology, 2017, 83, 2581-2588.	1.1	28
135	Pharmacokinetics and Time-Kill Study of Inhaled Antipseudomonal Bacteriophage Therapy in Mice. Antimicrobial Agents and Chemotherapy, 2020, 65, .	1.4	28
136	Pharmacokinetics and Tissue Distribution of Cisplatin and Conjugates of Cisplatin with Carboxymethyldextran and A5B7 Monoclonal Antibody in CD1 Mice. Journal of Pharmaceutical Sciences, 1997, 86, 1478-1483.	1.6	27
137	Mental health case conferences in primary care: Content and treatment decision making. Research in Social and Administrative Pharmacy, 2007, 3, 86-103.	1.5	27
138	The economic burden of guideline-recommended first line care for acute low back pain. European Spine Journal, 2018, 27, 109-116.	1.0	27
139	The pharmacokinetics of oxypurinol in people with gout. British Journal of Clinical Pharmacology, 2012, 74, 477-489.	1.1	26
140	Aging, Drugs, and Drug Metabolism. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2012, 67A, 137-139.	1.7	26
141	Deprescribing Opioids in Chronic Non-cancer Pain: Systematic Review of Randomised Trials. Drugs, 2020, 80, 1563-1576.	4.9	26
142	Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantation. British Journal of Clinical Pharmacology, 2010, 70, 567-579.	1.1	25
143	Tissue distribution of terbinafine in rats. Journal of Pharmaceutical Sciences, 2001, 90, 1817-1828.	1.6	24
144	Human subcutaneous tissue distribution of fluconazole: comparison of microdialysis and suction blister techniques. British Journal of Clinical Pharmacology, 2003, 56, 551-561.	1.1	24

#	Article	IF	Citations
145	Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate. British Journal of Clinical Pharmacology, 2008, 65, 326-333.	1.1	24
146	Extemporaneous product use in paediatric patients: a systematic review. International Journal of Pharmacy Practice, 2010, 16, 3-10.	0.3	24
147	Optimizing azole antifungal therapy in the prophylaxis and treatment of fungal infections. Current Opinion in Infectious Diseases, 2014, 27, 493-500.	1.3	24
148	Single-dose pharmacokinetics and cardiovascular effects of oral pimobendan in healthy cats. Journal of Veterinary Cardiology, 2016, 18, 310-325.	0.3	24
149	Which supplements can I recommend to my osteoarthritis patients?. Rheumatology, 2018, 57, iv75-iv87.	0.9	24
150	A comparative study regarding antibiotic consumption and knowledge of antimicrobial resistance among pharmacy students in Australia and Sri Lanka. PLoS ONE, 2019, 14, e0213520.	1.1	24
151	Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors. Journal of Heart and Lung Transplantation, 2001, 20, 431-438.	0.3	23
152	Cyclosporin C2 and C0 concentration monitoring in stable, long-term heart transplant recipients receiving metabolic inhibitors. Journal of Heart and Lung Transplantation, 2003, 22, 715-722.	0.3	23
153	Evidence and Practice in the Self-Management of Low Back Pain: Findings From an Australian Internet-based Survey. Clinical Journal of Pain, 2010, 26, 533-540.	0.8	23
154	Hospital survey on patient safety culture in Ethiopian public hospitals: a cross-sectional study. Safety in Health, $2017, 3, .$	0.7	23
155	Plasma protein distribution and its impact on pharmacokinetics of liposomal amphotericin B in paediatric patients with malignant diseases. European Journal of Clinical Pharmacology, 2007, 63, 165-172.	0.8	22
156	Treatment for osteoporosis in Australian residential aged care facilities: consensus recommendations for fracture prevention. Medical Journal of Australia, 2010, 193, 173-179.	0.8	22
157	Timing of Administration: For Commonly-Prescribed Medicines in Australia. Pharmaceutics, 2016, 8, 13.	2.0	22
158	Patterns of platinum drug use in an acute care setting: a retrospective study. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1561-1568.	1.2	22
159	Vincristine Chemotherapy Trials and Pharmacokinetics in Tasmanian Devils with Tasmanian Devil Facial Tumor Disease. PLoS ONE, 2013, 8, e65133.	1.1	21
160	Rethinking "long term―opioid therapy. BMJ, The, 2019, 367, l6691.	3.0	21
161	A phase I trial of the safety, tolerability and pharmacokinetics of cannabidiol administered as singleâ€dose oil solution and single and multiple doses of a sublingual wafer in healthy volunteers. British Journal of Clinical Pharmacology, 2021, 87, 2070-2077.	1.1	21
162	Bioequivalence: How, Why, and What Does it Really Mean?. Journal of Pharmacy Practice and Research, 2004, 34, 195-200.	0.5	20

#	Article	IF	CITATIONS
163	Nonsteroidal anti-inflammatory drugs (NSAIDs) in older people: Prescribing patterns according to pain prevalence and adherence to clinical guidelines. Pain, 2014, 155, 1814-1820.	2.0	20
164	The safety and tolerability of <i>Annona muricata</i> leaf extract: a systematic review. Journal of Pharmacy and Pharmacology, 2019, 72, 1-16.	1.2	20
165	An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 1395-1410.	1.5	19
166	PRECISE - pregabalin in addition to usual care for sciatica: study protocol for a randomised controlled trial. Trials, 2013, 14, 213.	0.7	19
167	Hepatic disposal of advanced glycation end products during maturation and aging. Experimental Gerontology, 2013, 48, 549-556.	1.2	19
168	Cross-national comparison of medication use in Australian and Dutch nursing homes. Age and Ageing, 2017, 46, 320-323.	0.7	19
169	Pharmacists and patients sharing decisions about medicines: Development and feasibility of a conversation guide. Research in Social and Administrative Pharmacy, 2019, 15, 682-690.	1.5	19
170	Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John's Wort. Clinical Pharmacokinetics, 2019, 58, 911-926.	1.6	19
171	Epidural Corticosteroid Injections for Sciatica. Spine, 2020, 45, E1405-E1415.	1.0	19
172	Effects of using text message interventions for the management of musculoskeletal pain: a systematic review. Pain, 2020, 161, 2462-2475.	2.0	19
173	Disposition and absorption of hydroxychloroquine enantiomers following a single dose of the racemate. Chirality, 1994, 6, 360-364.	1.3	18
174	Investigation of herb-drug interactions with ginkgo biloba in women receiving hormonal treatment for early breast cancer. SpringerPlus, 2013, 2, 126.	1,2	18
175	The Need to Strengthen the Role of the Pharmacist in Sri Lanka: Perspectives. Pharmacy (Basel,) Tj ETQq1 1 0.784	314 rgBT 0.6	/Oyerlock 1
176	An Electronic Clinical Decision Support System for the Management of Low Back Pain in Community Pharmacy: Development and Mixed Methods Feasibility Study. JMIR Medical Informatics, 2020, 8, e17203.	1.3	18
177	Generic medicines policies in the Asia Pacific region: ways forward. WHO South-East Asia Journal of Public Health, 2013, 2, 72.	1.7	18
178	Can Predictors of Response to NSAIDs Be Identified in Patients With Acute Low Back Pain?. Clinical Journal of Pain, 2009, 25, 659-665.	0.8	17
179	Evidence, Ethics and Medication Management in Older People. Journal of Pharmacy Practice and Research, 2010, 40, 148-152.	0.5	17
180	Clinical importance of the <i>CYP2C19*17</i> variant allele for voriconazole. British Journal of Clinical Pharmacology, 2011, 71, 137-138.	1.1	17

#	Article	IF	CITATIONS
181	Screening Education And Recognition in Community pHarmacies of Atrial Fibrillation to prevent stroke in an ambulant population aged ≥65â€years (SEARCH-AF stroke prevention study): a cross-sectional study protocol. BMJ Open, 2012, 2, e001355.	0.8	17
182	Barriers and facilitators to hospital pharmacists' engagement in medication safety activities: a qualitative study using the theoretical domains framework. Journal of Pharmaceutical Policy and Practice, 2018, 11, 2.	1.1	17
183	Determinants of antidepressant medication prescribing in elderly residents of aged care homes in Australia: A retrospective study. American Journal of Geriatric Pharmacotherapy, 2009, 7, 210-219.	3.0	16
184	Adherence, persistence and continuation with cholinesterase inhibitors in Alzheimer's disease. Australasian Journal on Ageing, 2012, 31, 164-169.	0.4	16
185	Assessment of in vitro and in vivo recovery of gallamine using microdialysis. Journal of Pharmacological and Toxicological Methods, 2000, 44, 519-525.	0.3	15
186	Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice. British Journal of Clinical Pharmacology, 2014, 78, 800-814.	1.1	15
187	The effects of educational interventions on pharmacists' knowledge, attitudes and beliefs towards low back pain. International Journal of Clinical Pharmacy, 2015, 37, 616-625.	1.0	15
188	Transcutaneous electric nerve stimulation (TENS) for acute low back pain: systematic review. Scandinavian Journal of Pain, 2019, 19, 225-233.	0.5	15
189	Efficacy and safety of a supplement combination on hand pain among people with symptomatic hand osteoarthritis an internet-based, randomised clinical trial the RADIANT study. Osteoarthritis and Cartilage, 2021, 29, 667-677.	0.6	15
190	Analytical Validation for a Series of Marker Compounds Used to Assess Renal Drug Elimination Processes. Therapeutic Drug Monitoring, 2001, 23, 39-46.	1.0	14
191	Development of a sufficient design for estimation of fluconazole pharmacokinetics in people with HIV infection. British Journal of Clinical Pharmacology, 2008, 66, 455-466.	1.1	14
192	Clinical pharmacology of analgesics in old age and frailty. Reviews in Clinical Gerontology, 2009, 19, 103-118.	0.5	14
193	PACE – the first placebo controlled trial of paracetamol for acute low back pain: statistical analysis plan. Trials, 2013, 14, 248.	0.7	14
194	Murine pharmacokinetics of rifapentine delivered as an inhalable dry powder. International Journal of Antimicrobial Agents, 2015, 45, 319-323.	1.1	14
195	Pharmacist-led admission medication reconciliation before and after the implementation of an electronic medication management system. International Journal of Medical Informatics, 2017, 101, 41-49.	1.6	14
196	What do Australian consumers, pharmacists and prescribers think about documenting indications on prescriptions and dispensed medicines labels?: A qualitative study. BMC Health Services Research, 2017, 17, 734.	0.9	14
197	Potential for pharmacokinetic interactions between <i>Schisandra sphenanthera</i> and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologicallyâ€based pharmacokinetic modelling approach. British Journal of Clinical Pharmacology, 2020, 86, 2080-2094.	1.1	14
198	The role of older patients' goals in GP decision-making about medicines: a qualitative study. BMC Family Practice, 2021, 22, 13.	2.9	14

#	Article	IF	Citations
199	The effects of different doses of inhaled bacteriophage therapy for Pseudomonas aeruginosa pulmonary infections in mice. Clinical Microbiology and Infection, 2022, 28, 983-989.	2.8	14
200	Manipulative therapy and/or NSAIDs for acute low back pain: design of a randomized controlled trial [ACTRN012605000036617]. BMC Musculoskeletal Disorders, 2005, 6, 57.	0.8	13
201	Psychiatric Drug Use Among Patients of a Community Mental Health Service. Disease Management and Health Outcomes, 2006, 14, 369-376.	0.3	13
202	Poloxamer 407 Increases the Recovery of Paracetamol in the Isolated Perfused Rat Liver. Journal of Pharmaceutical Sciences, 2011, 100, 334-340.	1.6	13
203	Diurnal variation in CYP1A2 enzyme activity in South Asians and Europeans. Journal of Pharmacy and Pharmacology, 2012, 65, 264-270.	1.2	13
204	A Scoping Review of Peer-led Education in Patient Safety Training. American Journal of Pharmaceutical Education, 2018, 82, 6110.	0.7	13
205	Exploring current and potential roles of Australian community pharmacists in gout management: a qualitative study. BMC Family Practice, 2018, 19, 54.	2.9	13
206	Paracetamol, NSAIDS and opioid analgesics for chronic low back pain: a network meta-analysis. The Cochrane Library, 0, , .	1.5	13
207	Physiologically-Based Pharmacokinetic Predictions of the Effect of Curcumin on Metabolism of Imatinib and Bosutinib: In Vitro and In Vivo Disconnect. Pharmaceutical Research, 2020, 37, 128.	1.7	13
208	The Effects of Cruciferous Vegetableâ€Enriched Diets on Drug Metabolism: A Systematic Review and Metaâ€Analysis of Dietary Intervention Trials in Humans. Clinical Pharmacology and Therapeutics, 2020, 108, 212-227.	2.3	13
209	Physiologicallyâ€based pharmacokinetic model predictions of interâ€ethnic differences in imatinib pharmacokinetics and dosing regimens. British Journal of Clinical Pharmacology, 2022, 88, 1735-1750.	1.1	13
210	Evaluating the Effectiveness of an Educational Intervention to Improve the Patient Safety Attitudes of Intern Pharmacists. American Journal of Pharmaceutical Education, 2017, 81, 5.	0.7	13
211	Warfarin metabolites: Stereochemical aspects of protein binding and displacement by phenylbutazone. Chirality, 1993, 5, 610-615.	1.3	12
212	A Comparison of Peripheral and Centrally Collected Cyclosporine A Blood Levels in Pediatric Patients Undergoing Stem Cell Transplant. Oncology Nursing Forum, 2005, 32, 73-77.	0.5	12
213	Measurement of urinary oxypurinol by high performance liquid chromatography–tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 2363-2368.	1.2	12
214	Community pharmacy compounding–impact on professional status. International Journal of Clinical Pharmacy, 2011, 33, 177-182.	1.0	12
215	"l have nine specialists. They need to swap notes!―Australian patients' perspectives of medicationâ€related problems following discharge from hospital. Health Expectations, 2017, 20, 1114-1120.	1.1	12
216	Management of vertebral compression fracture in general practice: BEACH program. PLoS ONE, 2017, 12, e0176351.	1.1	12

#	Article	IF	Citations
217	Immunomodulatory effects of pharmaceutical opioids and antipyretic analgesics: Mechanisms and relevance to infection. British Journal of Clinical Pharmacology, 2022, 88, 3114-3131.	1.1	12
218	Population pharmacokinetics of raltitrexed in patients with advanced solid tumours. British Journal of Clinical Pharmacology, 2004, 57, 416-426.	1.1	11
219	Time to Think Outside the Box? Proposals for a New Approach to Future Pharmacokinetic Studies of von Willebrand Factor Concentrates in People with von Willebrand Disease. Seminars in Thrombosis and Hemostasis, 2007, 33, 745-758.	1.5	11
220	Clinical Pharmacology of Chemotherapy Agents in Older People with Cancer. Current Gerontology and Geriatrics Research, 2011, 2011, 1-6.	1.6	11
221	Investigating paracetamol pharmacokinetics using venous and capillary blood and saliva sampling. Journal of Pharmacy and Pharmacology, 2012, 64, 705-711.	1.2	11
222	Investigating the Primary Care Management of Low Back Pain: AÂSimulated Patient Study. Journal of Pain, 2016, 17, 27-35.	0.7	11
223	Evaluation of the impact of pharmacist-led medication reconciliation intervention: a single centre pre–post study from Ethiopia. International Journal of Clinical Pharmacy, 2018, 40, 1209-1216.	1.0	11
224	Saliva for Precision Dosing of Antifungal Drugs: Saliva Population PK Model for Voriconazole Based on a Systematic Review Frontiers in Pharmacology, 2020, 11, 894.	1.6	11
225	The Prevalence of Opioid Analgesic Use in People with Chronic Noncancer Pain: Systematic Review and Meta-Analysis of Observational Studies. Pain Medicine, 2021, 22, 506-517.	0.9	11
226	Amphotericin B Dose Optimization in Children with Malignant Diseases. Chemotherapy, 2007, 53, 142-147.	0.8	10
227	Generic medicines literacy $\hat{a} \in \hat{a}$ minimising the potential for patient confusion. Medical Journal of Australia, 2010, 192, 368-369.	0.8	10
228	Validation of a survey tool to assess the patient safety attitudes of pharmacy students. BMJ Open, 2015, 5, e008442.	0.8	10
229	Evaluating the effectiveness of a peer-led education intervention to improve the patient safety attitudes of junior pharmacy students: a cross-sectional study using a latent growth curve modelling approach. BMJ Open, 2015, 5, e010045.	0.8	10
230	Medication reconciliation as a medication safety initiative in Ethiopia: a study protocol. BMJ Open, 2016, 6, e012322.	0.8	10
231	Consumer perspectives of medication-related problems following discharge from hospital in Australia: a quantitative study. International Journal for Quality in Health Care, 2016, 28, 391-397.	0.9	10
232	The Challenges of Treating Sciatica Pain in Older Adults. Drugs and Aging, 2016, 33, 779-785.	1.3	10
233	Delivering the right information to the right person at the right time to facilitate deprescribing in hospital: a mixed methods multisite study to inform decision support design in Australia. BMJ Open, 2019, 9, e030950.	0.8	10
234	Attitudes to Drug Use in Residential Aged Care Facilities: A Cross-Sectional Survey of Nurses and Care Staff. Drugs and Aging, 2021, 38, 697-711.	1.3	10

#	Article	IF	CITATIONS
235	National Medicines Policy 2.0: a vision for the future. Australian Prescriber, 2020, 43, 24-26.	0.5	10
236	Health Literacy and Appropriateness of <scp>Selfâ€Care</scp> and Pain Management in Osteoarthritis: An Understanding of the Patient's Perspective. Arthritis Care and Research, 2023, 75, 848-859.	1.5	10
237	Pharmacokinetic considerations of regional administration and drug targeting: Influence of site of input in target tissue and flux of binding protein. Journal of Pharmacokinetics and Pharmacodynamics, 1996, 24, 369-387.	0.6	9
238	Decision Support Tool to Individualize Cyclosporine Dose in Stable, Long-term Heart Transplant Recipients Receiving Metabolic Inhibitors: Overcoming Limitations of Cyclosporine C2 Monitoring. Journal of Heart and Lung Transplantation, 2006, 25, 1223-1229.	0.3	9
239	Specialised Compounding-Practices and Opinions of Australian Community Pharmacists. Journal of Pharmacy Practice and Research, 2007, 37, 260-264.	0.5	9
240	In-vitro distribution of terbinafine in rat and human blood. Journal of Pharmacy and Pharmacology, 2010, 54, 277-281.	1.2	9
241	Disposition of amphotericin B in the isolated perfused rat liver. Journal of Pharmacy and Pharmacology, 2010, 56, 35-41.	1.2	9
242	Loperamide inhibits the biliary excretion of irinotecan (CPT-11) in the rat isolated perfused liverâ€. Journal of Pharmacy and Pharmacology, 2010, 57, 39-45.	1.2	9
243	The Influence of Old Age and Poloxamer-407 on the Hepatic Disposition of Diazepam in the Isolated Perfused Rat Liver. Pharmacology, 2012, 90, 233-241.	0.9	9
244	Characterizing specialized compounding in community pharmacies. Research in Social and Administrative Pharmacy, 2012, 8, 240-252.	1.5	9
245	Participation of pharmacists in clinical trial recruitment for low back pain. International Journal of Clinical Pharmacy, 2014, 36, 986-994.	1.0	9
246	OPAL: a randomised, placebo-controlled trial of opioid analgesia for the reduction of pain severity in people with acute spinal pain. Trial protocol. BMJ Open, 2016, 6, e011278.	0.8	9
247	Comparison of effect sizes between enriched and nonenriched trials of analgesics for chronic musculoskeletal pain: a systematic review. British Journal of Clinical Pharmacology, 2017, 83, 2347-2355.	1.1	9
248	Exploring the enablers and barriers to implementing the Medication Appropriateness Tool for Comorbid Health conditions during Dementia (MATCH-D) criteria in Australia: a qualitative study. BMJ Open, 2017, 7, e017906.	0.8	9
249	Pharmacokinetic assessment of constituents of <i>Boswellia serrata</i> , pine bark extracts, curcumin in combination including methylsulfonylmethane in healthy volunteers. Journal of Pharmacy and Pharmacology, 2019, 72, 121-131.	1.2	9
250	Antimicrobial Stewardship Audit and Feedback rounds: moving beyond the restricted antibiotic list and the impact of electronic systems. Internal Medicine Journal, 2020, 51, 1876-1883.	0.5	9
251	Effectiveness of an electronic patient-centred self-management tool for gout sufferers: a cluster randomised controlled trial protocol. BMJ Open, 2017, 7, e017281.	0.8	9
252	Pharmacokinetics of caspofungin acetate to guide optimal dosing in cats. PLoS ONE, 2017, 12, e0178783.	1.1	9

#	Article	IF	CITATIONS
253	A Phase I Study of the Pharmacokinetics and Safety of Passive Immunotherapy with Caprine Anti-HIV Antibodies, PEHRG214, in HIV-1-Infected Individuals. HIV Clinical Trials, 2004, 5, 91-98.	2.0	8
254	Hepatobiliary Disposition of Liposomal Amphotericin B in the Isolated Perfused Rat Liver. Journal of Pharmaceutical Sciences, 2005, 94, 169-176.	1.6	8
255	A Pharmacometric Approach to Investigate the Impact of Methylxanthine Abstinence and Caffeine Consumption on CYP1A2 Activity. Drug Metabolism and Disposition, 2013, 41, 1957-1966.	1.7	8
256	Efficacy and harms of orally, intramuscularly or intravenously administered glucocorticoids for sciatica: A systematic review and metaâ€analysis. European Journal of Pain, 2020, 24, 518-535.	1.4	8
257	TEXT4myBACK – The Development Process of a Self-Management Intervention Delivered Via Text Message for Low Back Pain. Archives of Rehabilitation Research and Clinical Translation, 2021, 3, 100128.	0.5	8
258	SPARSE DRUG CONCENTRATION DATA ANALYSIS USING A POPULATION APPROACH: A VALUABLE TOOL IN CLINICAL PHARMACOLOGY. Clinical and Experimental Pharmacology and Physiology, 1996, 23, 995-999.	0.9	7
259	Medicines and disease information needs of older Arabicâ€speaking Australians. Australasian Journal on Ageing, 2013, 32, 28-33.	0.4	7
260	Prediction of plasma caffeine concentrations in young adolescents following ingestion of caffeinated energy drinks: a Monte Carlo simulation. European Journal of Pediatrics, 2015, 174, 1671-1678.	1.3	7
261	Patterns of high-risk prescribing and other factors in relation to receipt of a home medicines review: a prospective cohort investigation among adults aged 45 years and over in Australia. BMJ Open, 2019, 9, e027305.	0.8	7
262	Efficacy and Safety of Low-dose Codeine-containing Combination Analgesics for Pain. Clinical Journal of Pain, 2019, 35, 836-843.	0.8	7
263	TEXT4myBACK: A Text Message Intervention to Improve Function in People With Low Back Painâ€"Protocol of a Randomized Controlled Trial. Physical Therapy, 2021, 101, .	1.1	7
264	Protocol for the Controlled evaLuation of Angiotensin Receptor blockers for COVID-19 respiraTorY disease (CLARITY): a randomised controlled trial. Trials, 2021, 22, 573.	0.7	7
265	The Participation of Cytochrome P450 3A4 in Clozapine Biotransformation Is Detected in People With Schizophrenia by High-Throughput In Vivo Phenotyping. Journal of Clinical Psychopharmacology, 2010, 30, 629-631.	0.7	6
266	Prevalence of Potentially Harmful Drug Interactions in Older People in Australian Aged are Facilities. Journal of Pharmacy Practice and Research, 2012, 42, 33-36.	0.5	6
267	Relationships Between Pharmacovigilance, Molecular, Structural, and Pathway Data: Revealing Mechanisms for Immuneâ€Mediated Drugâ€Induced Liver Injury. CPT: Pharmacometrics and Systems Pharmacology, 2015, 4, 426-441.	1.3	6
268	Australian pharmacists' perspectives on physician-assisted suicide (PAS): thematic analysis of semistructured interviews. BMJ Open, 2019, 9, e028868.	0.8	6
269	Studies of the mechanism of crystal growth of hexamethylmelamine. Journal of Crystal Growth, 1990, 104, 355-364.	0.7	5
270	Application of a high-performance liquid chromatographic assay for the neuromuscular blocker gallamine to analysis of rat plasma, muscle and microdialysate samples. Biomedical Applications, 2001, 754, 467-475.	1.7	5

#	Article	IF	Citations
271	Muscle Distribution of the Neuromuscular Blocker gallamine Using Microdialysis. Journal of Pharmaceutical Sciences, 2002, 91, 769-775.	1.6	5
272	Pharmacists' views on implementing a disease state management program for low back pain. Australian Journal of Primary Health, 2016, 22, 211.	0.4	5
273	An evaluation of garlic products available in Australian pharmacies–From the label to the laboratory. Journal of Herbal Medicine, 2018, 14, 61-67.	1.0	5
274	Management of gout in older people. Journal of Pharmacy Practice and Research, 2019, 49, 90-97.	0.5	5
275	Enhanced serum immunoglobulin G clearance in myotonic dystrophy-associated hypogammaglobulinemia: a case series and review of the literature. Journal of Medical Case Reports, 2019, 13, 338.	0.4	5
276	Paracetamol is ineffective for acute low back pain even for patients who comply with treatment: complier average causal effect analysis of a randomized controlled trial. Pain, 2019, 160, 2848-2854.	2.0	5
277	Pharmacists' and older adults' perspectives on the benefits and barriers of Home Medicines Reviews – a qualitative study. Journal of Health Services Research and Policy, 2020, 25, 77-85.	0.8	5
278	Ibudilast for prevention of oxaliplatin-induced acute neurotoxicity: a pilot study assessing preliminary efficacy, tolerability and pharmacokinetic interactions in patients with metastatic gastrointestinal cancer. Cancer Chemotherapy and Pharmacology, 2020, 86, 547-558.	1.1	5
279	Pharmacoepidemiology of metaraminol in critically ill patients with shock in a tertiary care hospital. Australian Critical Care, 2021, 34, 573-579.	0.6	5
280	Investigating knowledge regarding antibiotics among pharmacy and allied health sciences students in a Sri Lankan university. Journal of Infection in Developing Countries, 2018, 12, 726-732.	0.5	5
281	Osteoarthritis management: Does the pharmacist play a role in bridging the gap between what patients actually know and what they ought to know? Insights from a national online survey. Health Expectations, 2022, 25, 936-946.	1.1	5
282	Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinib. European Journal of Clinical Pharmacology, 2022, 78, 597-611.	0.8	5
283	Specialized compounding in community pharmacies: Organizational perspective. Journal of the American Pharmacists Association: JAPhA, 2010, 50, 354-361.	0.7	4
284	Pharmacometrics: an underused resource in Australian clinical research. Medical Journal of Australia, 2014, 200, 82-83.	0.8	4
285	PRECISE â€" pregabalin in addition to usual care: statistical analysis plan. Trials, 2016, 17, 53.	0.7	4
286	A Strategy to Refine the Phenotyping Approach and Its Implementation to Predict Drug Clearance: A Physiologically Based Pharmacokinetic Simulation Study. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 798-808.	1.3	4
287	Pharmacokinetics of Anticancer Drugs Used in Treatment of Older Adults With Colorectal Cancer: A Systematic Review. Therapeutic Drug Monitoring, 2019, 41, 553-560.	1.0	4
288	Efficacy and safety of a supplement combination for hand osteoarthritis pain: protocol for an internet-based randomised placebo-controlled trial (The RADIANT study). BMJ Open, 2020, 10, e035672.	0.8	4

#	Article	IF	Citations
289	Medication incident recovery and prevention utilising an Australian community pharmacy incident reporting system: the QUMwatch study. European Journal of Clinical Pharmacology, 2021, 77, 1381-1395.	0.8	4
290	Dose equivalence between metaraminol and norepinephrine in critical care. British Journal of Clinical Pharmacology, 2022, 88, 303-310.	1.1	4
291	Renal handling of warfarin metabolites in man. European Journal of Pharmaceutical Sciences, 1994, 1, 189-193.	1.9	3
292	Estimation of the rate and extent of chiral inversion using linear systems analysis. Chirality, 1995, 7, 632-635.	1.3	3
293	Telaprevir and Boceprevir. Therapeutic Drug Monitoring, 2013, 35, 414-415.	1.0	3
294	Comparative efficacy trials with no placebo group cannot determine efficacy. BMJ, The, 2015, 350, h3292-h3292.	3.0	3
295	Improving adherence to urateâ€lowering therapy in people living with gout. International Journal of Rheumatic Diseases, 2019, 22, 542-544.	0.9	3
296	OASISâ€"a randomised, placebo-controlled trial of oral glucocorticoids for leg pain in patients with acute sciatica: trial protocol. BMJ Open, 2020, 10, e040559.	0.8	3
297	Inability of Current Dosing to Achieve Carboplatin Therapeutic Targets in People with Advanced Non-Small Cell Lung Cancer: Impact of Systemic Inflammation on Carboplatin Exposure and Clinical Outcomes. Clinical Pharmacokinetics, 2020, 59, 1013-1026.	1.6	3
298	The nature, severity and causes of medication incidents from an Australian community pharmacy incident reporting system: The QUMwatch study. British Journal of Clinical Pharmacology, 2021, 87, 4809-4822.	1.1	3
299	Comparison of metaraminol versus no metaraminol on time to resolution of shock in critically ill patients. European Journal of Hospital Pharmacy, 2023, 30, 214-220.	0.5	3
300	OUP accepted manuscript. International Journal of Pharmacy Practice, 2022, , .	0.3	3
301	OPAL: a randomised, placebo-controlled trial of opioid analgesia for the reduction of pain severity in people with acute spinal pain—a statistical analysis plan. Trials, 2022, 23, 212.	0.7	3
302	Better measuring and reporting of adverse events are needed in back pain trials of non-drug interventions. BMJ, The, 2022, 377, o1055.	3.0	3
303	Knowledge and satisfaction of pharmacists attending an educational workshop on evidence-based management of low back pain. Australian Journal of Primary Health, 2015, 21, 126.	0.4	2
304	An improved cytochrome P450 phenotyping cocktail with a simplified and highly sensitive UHPLC-MS/MS assay in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2020, 1140, 122013.	1.2	2
305	Targeting neurotrophic factors for low back pain and sciatica: a systematic review and meta-analysis. Rheumatology, 2022, 61, 2243-2254.	0.9	2
306	Beyond Conventional Cancer Treatments: "The Use of Complementary Therapies During Cancer Treatment: Implications for Clinicians". , 2009, , 285-315.		2

#	Article	IF	CITATIONS
307	Enhancing generational change in patient safety attitudes through peer leadership. BMJ Simulation and Technology Enhanced Learning, 2016, 2, 87-89.	0.7	2
308	Population Pharmacokinetics of Oral-Based Administration of Cannabidiol in Healthy Adults: Implications for Drug Development. Cannabis and Cannabinoid Research, 2022, , .	1.5	2
309	Physiologically Based Pharmacokinetic Modeling Approaches for Patients With SARSâ€CoVâ€2 Infection: A Case Study With Imatinib. Journal of Clinical Pharmacology, 2022, , .	1.0	2
310	Documenting antibiotic use in transition from intensive care unit to wards. Journal of Pharmacy Practice and Research, 2016, 46, 91-92.	0.5	1
311	Is it ethical to prescribe paracetamol for acute low back pain and osteoarthritis?. Lancet Rheumatology, The, 2019, 1, e140-e142.	2.2	1
312	Adverse drug reactions due to opioid analgesic use in New South Wales, Australia: a spatial-temporal analysis. BMC Pharmacology & Doctor (2019, 2019, 20, 55.)	1.0	1
313	Response to comment by Bhatia. European Journal of Pain, 2020, 24, 1209-1210.	1.4	1
314	Investigating knowledge regarding antibiotics and antimicrobial resistance among pharmacy students in Australian universities. Journal of Pharmacy Practice and Research, 2021, 51, 54-61.	0.5	1
315	Building a pharmacy workforce from the ground up to support the <scp>COVID</scp> â€19 vaccine rollout: lessons learned and recommendations. Journal of Pharmacy Practice and Research, 0, , .	0.5	1
316	Anticoagulation Control in Hospitalised Patients on Warfarin. Journal of Pharmacy Practice and Research, 2008, 38, 292-295.	0.5	0
317	Frailty Should be Assessed Using Validated Scales. Drugs and Aging, 2010, 27, 687.	1.3	0
318	Reply to "What Types of Candida Infections Should Be Included When Evaluating Breakthrough Infections during Posaconazole Prophylaxis?― Antimicrobial Agents and Chemotherapy, 2013, 57, 2906-2906.	1.4	0
319	The role of pharmacists in the management of Arabic-speaking people with diabetes mellitus: a systematic review. Journal of Pharmaceutical Health Services Research, 2013, 4, 239-248.	0.3	0
320	Media and Medical Research Miracles: Sorting the Spin. Journal of Pharmacy Practice and Research, 2013, 43, 258-259.	0.5	0
321	Combination drug therapy for low back pain. The Cochrane Library, 0, , .	1.5	0
322	Therapeutic Drug Monitoring in Older People. , 2016, , 213-229.		0
323	Authors' reply to the comment by Durg. European Journal of Pain, 2017, 21, 400-400.	1.4	0
324	Safe prescribing, rocket science and consumers. Journal of Pharmacy Practice and Research, 2018, 48, 4-6.	0.5	0

#	Article	IF	CITATIONS
325	66â€Preventing overtreatment in older age by prioritising medicines. , 2018, , .		0
326	Editorial: Drug delivery in older people – unique challenges and important opportunities. Advanced Drug Delivery Reviews, 2018, 135, 1-2.	6.6	0
327	Low-Dose Amitriptyline for Chronic Low Back Pain. JAMA Internal Medicine, 2019, 179, 450.	2.6	O
328	45 Patient and clinician interventions for opioid analgesic deprescribing in chronic non-cancer pain: a systematic review. , 2019, , .		0
329	Healthcare expenditure and its predictors in a cohort of Australians living with sciatica. European Spine Journal, 2021, 30, 878-885.	1.0	0
330	Dosing Errors: Age-Related Changes in Pharmacokinetics. , 2010, , 127-135.		0
331	Misuse of Formulations in the Aged Care Setting. , 2010, , 95-104.		0
332	The Ethics of Prescribing Medications to Older People. , 2010, , 29-42.		0
333	27 Increasing prescription of opioid analgesics and neuropathic pain medicines for spinal pain in australia. , 2018, , .		0
334	Efficacy and safety of metaraminol in critically ill patients with shock: a systematic review. Journal of Pharmacy Practice and Research, 0, , .	0.5	0